PatientsVille.com Logo


Auranofin Medical Research Studies

Up-to-date List of Auranofin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Auranofin Medical Research Studies

Rank Status Study
1 Recruiting Auranofin PK Following Oral Dose Administration
Condition: Amoebiasis
Intervention: Drug: Auranofin
Outcome Measures: Plasma concentrations of gold following 7 once daily doses of Auranofin;   Type, frequency and severity of treatment-emergent adverse events (TEAEs) to 14 days after administration of the first dose;   Type, frequency and severity of Serious AEs (SAEs) to the end of study
2 Not yet recruiting Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
Condition: HIV
Intervention: Drug: Auranofin
Outcome Measures: Safety and Tolerability;   Change from baseline in measures of the HIV latent reservoir during Auranofin therapy
3 Recruiting Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome
Condition: Pain
Interventions: Drug: Auranofin;   Other: placebo;   Other: questionnaire administration
Outcome Measures: Percentage of patients who report having experienced the paclitaxel-induced pain syndrome (PIAPS) for one week after paclitaxel after enrollment to the current trial, assessed by the Modified Brief Pain Inventory Scale (BPI);   Proportion of patients who rate their pain as >= 4 assessed by the BPI;   Area under the curve for other pain items on the modified BPI;   Locations of pain;   Average responses to questions from the modified BPI;   Incidence of adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4;   Pain descriptions and locations as measured by the PIAPS Symptom Summary
4 Recruiting Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Leukemia, Prolymphocytic
Intervention: Drug: Auranofin
Outcome Measures: Response Rate;   type, incidence, severity, seriousness and relationship to Auranofin of adverse events and any laboratory abnormalities
5 Recruiting PKCi & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer
Conditions: Adenosquamous Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sirolimus;   Drug: Auranofin
Outcome Measures: Progression-free survival rate measured by survival out to 4 months.;   Survival time in this population in comparison to recent historical controls (exemplified by survival of the squamous histology cohort of the Scagliotti et al trial of cisplatin with pemetrexed or gemcitabine for advanced NSCLC).;   Overall response rate (CR or PR);   Adverse Events (AE) profile and safety of the regimen using the CTCAE v4.0.

These studies may lead to new treatments and are adding insight into Auranofin etiology and treatment.

A major focus of Auranofin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Auranofin